OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.9 SEK | -0.50% |
|
+1.53% | +28.72% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +28.72% | 65.36M | B | ||
| +6.42% | 70.2B | A | ||
| +31.48% | 10.12B | A- | ||
| +28.34% | 4.83B | B- | ||
| -20.02% | 4.53B | A- | ||
| +18.94% | 3.59B | - | ||
| +22.06% | 2.18B | - | - | |
| -36.80% | 1.8B | C- | ||
| -42.53% | 1.74B | - | ||
| -0.50% | 1.64B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORX Stock
- Ratings Orexo AB
